Hypertension is considered the most common disorder in the general population. It is both a health and a financial problem worldwide.
C A R D I A C FA I L U R E R E V I E W rapid BP reduction can result in decreased perfusion of vital organs and even enhance ischaemic lesions. 7 
Anti-hypertensive Treatment in Elderly Patients
Considering the physiological alterations resulting from ageing and the presence of multiple comorbidities, treatment of hypertension in elderly patients poses a significant challenge to treatment teams.
Age can affect the pharmacokinetics of the medication used and decrease the patient's capability to comply with treatment. 8 Age also has a significant impact on the function of all body systems, particularly the cardiovascular system. Processes occurring in the arteries contribute to increased arterial stiffness and calcium accumulation, as well as quantitative and qualitative alterations in vascular wall collagen. Consequences include atherosclerosis and decreased vascular elasticity, impaired sino-atrial node function, and decreased heart rate. All this leads to increased SBP, decreased left ventricular ejection fraction, and impaired response to orthostatic changes, seen in elderly patients. There is a risk of isolated systolic hypertension or diastolic heart failure. 9, 10 Ageing also significantly affects the central nervous system (CNS). Cerebral perfusion decreases by 15-20 % in the elderly. The number of neurons in the grey matter, cerebellum, and hippocampus also declines. In consequence, elderly individuals may experience impaired memory or other cognitive functions, which restricts their activity and mobility in daily living.
Ageing is also apparent in the kidneys, with structural and functional changes taking place. Both kidney weight and glomerular filtration are reduced. Between the ages of 40 and 90, kidney performance can decrease by up to 50 %. 11 Age also affects the regulation of urine density and pH by the kidneys. 12 In the digestive tract, ageing manifests itself in decreased oesophageal motor activity, referred to as presbyoesophagus. 13 Another ageing-related process in the digestive system is the decrease in digestive juice acidity because of gastric mucosal atrophy. 14 The respiratory system is also affected by ageing. Its impact mainly involves the gradual decrease in chest mobility because of costal cartilage ossification, and reduced muscle power. These processes increase susceptibility to bronchial infection. 15 Changes in the immune system are also significant in terms of the risk of infection, 
Frailty Definitions and Measures
Multiple studies have shown that frail older people are at high risk of developing adverse outcomes such as disability, 23, 24 hospitalisation, 23 institutionalisation, 25 lower quality of life 26, 27 and premature death. 28 However, there is still no consensus regarding the conceptual and operational definition of frailty. [29] [30] [31] Fundamentally, frailty is a medical concept, and as a result, it is often defined in the context of problems in physical functioning. An example of such a definition is the one produced by Fried et al. 23 These researchers define frailty as a "biologic syndrome of decreased reserve and resistance to stressors, resulting from cumulative declines across multiple physiologic systems, causing vulnerability to adverse outcomes." 23 Their operationalisation of frailty, the phenotype of frailty, is extensively used in both research and practice. The phenotype assesses frailty based on five criteria: physical inactivity, low walking speed, weight loss, exhaustion and low grip strength. 23 The debate on frailty is mainly focused on whether frailty should be defined only in terms of physical factors or whether psychological and social factors should be included as well. 32 According to Bergman et al., 30 frailty provides a conceptual basis for moving away from organ-and disease-based approaches towards a health-based, integrative approach. An integrative approach is important because it starts from a holistic point of view and thus regards how humans function as a whole organism; a partial view could lead to fragmentation of care 33, 34 and consequently to reduced quality of care being provided to frail older people. A definition of frailty that expresses this integrative approach is as follows: "Frailty is a dynamic state affecting an individual who experiences losses in one or more domains of human functioning (physical, psychological, social), which is caused by the influence of a range of variables and which increases the risk of adverse outcomes." 33 Recently, Sutton et al. 29 identified 38 multi-component frailty measures. One of these measures is the frequently used and cited Frailty Index developed by Mitnitski et al. 35 The Frailty Index is based on the cumulative deficit approach and proposes that frailty can be assessed by evaluating a large number of non-specified age-associated health deficits, usually at least 30. 35, 36 Because both the phenotype of frailty 23 and the Frailty Index 35 are 41 .
According to Sutton et al., 29 the TFI has been the most extensively examined in terms of psychometric properties and also has the most robust evidence of reliability and validity. Nevertheless, the definition of frailty and adverse outcomes that best suits the unique needs of researchers, healthcare professionals (such as clinicians, nurses, physiotherapists and occupational therapists) and policymakers conducting the assessment of frailty determines the choice of the appropriate measure of frailty. also be included, and protein deficiency must be compensated for. 43 Elderly patients can benefit from an interdisciplinary approach to care. Important factors include early identification of polypharmacy by the treatment team, implementing appropriate treatment for comorbidities, identifying cognitive impairment and low mood, providing psychological support and preventing falls. 44 In recent years, a number of prevention programs have been launched that promote screening tests enabling quick identification of patients who are frail or at risk of frailty such as the FRAIL scale 39 and the TFI. 41 Consistent prevention activity programs have become a priority for many health care facilities and teams. In accordance with the guidelines, screening for frailty should include all patients older than 70 years who have one or more of the following symptoms: significant weight loss in the preceding year, fatigability, overall weakness, and a decrease in physical activity interfering with normal activity. 45 Frailty syndrome is undoubtedly a challenge for multidisciplinary teams providing health care for geriatric patients. In clinical practice, special attention should be paid to frail elderly patients, who should receive tailored treatment.
Future activities in the field of frailty prevention and identification should include the development of screening tests and minimising the health impact of frailty, with particular attention paid to at-risk groups of patients. A key issue related to frailty is social awareness, as the consequences of the syndrome are both health-related and social.
The latter include increased morbidity, more frequent hospitalisations, loss of one's social position and roles, and the risk of social isolation.
Social acceptance may play a significant role in adapting to changes imposed by frailty syndrome. 46 Although no multi-centre studies exist that demonstrate differences in care for frail patients, the group certainly deserves more attention. As these patients are at a higher risk of complications following invasive procedures and of adverse effects from medication, they should be managed with extra caution.
Orthostatic Hypotension
Orthostatic hypotension (OH) results from an autonomic nervous system dysfunction, and involves maladjustment of the cardiovascular system to sudden changes in body position. 
Falls
Falls among elderly patients are strictly associated with ageing processes in the body, affecting the nervous system, the musculoskeletal system, vision and hearing, and blood vessels.
Chronic diseases, including hypertension, deteriorate baroreceptor function and result in irreversible changes in cerebral and coronary circulation. The risk of sudden drops in BP also rises. Organ complications of chronic hypertension, ischaemic heart disease and heart failure increase the risk of syncope, which often results in falls. 59 Anti-hypertensive treatment and medication side effects are also significant. 60 Comorbidities and decreased mobility also contribute to falls in elderly patients. Besides multimorbidity associated with cerebral and coronary atherosclerosis, age itself -with the resulting decrease in posture stability -can contribute to falls resulting in injury that limits the patient's independence and increases both their dependence on others and the risk of subsequent incidents. Physiologically, ageing processes involve age-associated memory impairment or age-related cognitive decline. 63 Currently, symptoms of dementia are found in 2-10 out of 1000 patients aged >70, and 20-40 out of 1000 patients aged ≥80. It becomes significantly more common with age, though it will not occur in 50 % of 85-year-olds, and therefore cannot be exclusively attributed to ageing. . 68 Concurrent frailty and/or cognitive impairment in elderly patients is associated with a worse perception of health, increased number of comorbidities, and social isolation of the patient. 23 It can also be suspected to interfere with treatment adherence. 69 Few studies are available on the association between the components of geriatric syndrome and adherence to treatment. Those papers that discuss associations between frailty and adherence are based on populations with diseases other than hypertension. 70, 71 There is a discussion in the available literature regarding the impact of frailty syndrome on adherence. 70, 72 In a study by Jankowska et al., frailty was found in 63.9 % of hypertensive patients and was associated with worse adherence to anti-hypertensive treatment. Among factors negatively correlated with adherence, the authors identified being alone and some determinants
of frailty in accordance with the TFI (such as being alone, death of a loved one, serious illness, serious illness of the partner, and divorce or ending a relationship in the preceding year). 72 In a study by Koizumi et al., 73 frailty in hypertensive patients was associated with limited physical activity, lower body weight, difficulties in ingesting solid foods and performing daily activities, and limitations in performing complex activities of daily living, correlated with the prevalence, treatment and control of hypertension. 73 In another study, Talegawkar et al. 74 investigated associations between frailty and adherence to the Mediterranean diet, and found that non-frail patients were more compliant with dietary recommendations than frail patients. 74 Contrary to the above, Chao et al. report better adherence in frail patients, though not in the hypertensive population. 70 The authors link better adherence found in frail patients to their older age, stating that elderly patients pay more attention to their illness and symptoms, and are thus more compliant with the prescribed treatment plans. Other authors suggest that the differences in adherence between frail elderly patients and younger individuals can be associated with cognitive impairment and with the less accurate reporting of adherence by the elderly, which may be the cause of artificially high results. 75 A similar discussion exists with regard to correlations between elderly age and adherence to anti-hypertensive treatment. Karakurt et al. 76 and Jassim Al Khaja et al. 77 report that patients above 70 years take their medication less consistently than younger patients. In research by Jankowska et al., younger age was associated with better reported health behaviours in the 'health practices' domain, 78 but worse adherence to pharmaceutical treatment. 79 Jackevicius et al. 80 and Lam et al. 81 report a correlation between younger age and better pharmaceutical adherence. On the other hand, some publications indicate older age as a predictor of better adherence to medication. 82, 83 In elderly patients, factors decreasing adherence can also include multimorbidity and polypharmacy, adverse effects of treatment, unfulfilled expectations regarding treatment outcomes, and adverse drug interactions.
Treatment outcomes do not always match patient expectations, which can result in discontinuation of the prescribed medication. As to the better adherence to treatment found in elderly patients, it has been explained by the presence of comorbidities, which makes patients perceive themselves as very ill and take the prescribed treatment seriously. 84 Identifying the causes of non-adherence to pharmaceutical treatment is a key factor in planning therapeutic interventions aimed at increasing control, preventing complications, and improving long-term outcomes and any adverse effects of treatment. Precise identification of contributors to low medication adherence is crucial for improving treatment effectiveness and for distinguishing those patients in need of additional supervision in order to decrease the risk of complications from untreated hypertension. Diagnosis of frailty and of the associated difficulties in adhering to treatment allows for targeting the elderly patients with a poorer prognosis and at risk of complications from untreated or undertreated hypertension, and for planning interventions to improve hypertension control.
Conclusions
The importance of high BP and the effect of lowering BP in older adults remain controversial because of the mixed evidence in this population.
For frail elderly patients, consider starting treatment if the SBP is 160 mmHg or higher. If the patient is severely frail and has a short life expectancy, a SPB target of 160-190 mmHg may be reasonable.
If the SBP is below 140 mmHg, anti-hypertensive medications can be reduced as long as they are not indicated for other conditions. In general, no more than two anti-hypertensive medications should be prescribed to avoid unnecessary administration of a large number of medications. There is little direct evidence to inform the risks and benefits of using anti-hypertensive medications to treat chronic health conditions when significant frailty is present. Since the frail elderly are vulnerable to poor health outcomes, it is important to assess the risk/benefit ratio of healthcare interventions, including drug therapy.
Future clinical trials need to consider modifications to safely include frail older adults, and treatment recommendations for hypertension, specific to the frail elderly, should consider inclusion of evidence beyond randomised controlled trials. Management of hypertension in frail elderly people is a newly emerging problem, and it should be pointed out that work on frailty in this context will only be relevant if effective health promotion, prevention, treatment, rehabilitation, and care interventions can be identified. ■
